Cargando…
Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review
OBJECTIVES: The presence of autoimmune events were recorded in patients receiving immune checkpoint inhibitors. MATERIALS & METHODS: Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012–2019. RESULTS: A total of 554 patients received ICIs of whi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787148/ https://www.ncbi.nlm.nih.gov/pubmed/33437507 http://dx.doi.org/10.2144/fsoa-2020-0129 |
_version_ | 1783632770538405888 |
---|---|
author | Schmerling, Rafael A Buzaid, Antonio C Haddad, Carolina K Schutz, Fabio AB Kater, Fabio R Pimenta, Juliana Maluf, Fernando William, William N Lopes, Camila Bromberg, Dafne R Oliveira, Ana C Golmia, Ricardo Scheinberg, Morton |
author_facet | Schmerling, Rafael A Buzaid, Antonio C Haddad, Carolina K Schutz, Fabio AB Kater, Fabio R Pimenta, Juliana Maluf, Fernando William, William N Lopes, Camila Bromberg, Dafne R Oliveira, Ana C Golmia, Ricardo Scheinberg, Morton |
author_sort | Schmerling, Rafael A |
collection | PubMed |
description | OBJECTIVES: The presence of autoimmune events were recorded in patients receiving immune checkpoint inhibitors. MATERIALS & METHODS: Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012–2019. RESULTS: A total of 554 patients received ICIs of which 123 developed an immune related adverse event. Twenty one (17%) with toxicity were identified as having a pre-existing autoimmune disease and 88 required treatment with corticosteroids or hormone replacement. Thirty two (26%) out of 123 had to temporarily discontinue ICIs due to autoimmune manifestations. Endocrine and skin manifestations were the most prevalent immune disorders in our cohort. In melanoma better efficacy was seen in patients with immune toxicity. CONCLUSION: Autoimmune diseases appear in patients receiving ICIs in this real world experience. Our results differ from other series on the frequency of autoimmunity. Complete discontinuation of ICIs due to autoimmunity was rare. |
format | Online Article Text |
id | pubmed-7787148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-77871482021-01-11 Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review Schmerling, Rafael A Buzaid, Antonio C Haddad, Carolina K Schutz, Fabio AB Kater, Fabio R Pimenta, Juliana Maluf, Fernando William, William N Lopes, Camila Bromberg, Dafne R Oliveira, Ana C Golmia, Ricardo Scheinberg, Morton Future Sci OA Short Communication OBJECTIVES: The presence of autoimmune events were recorded in patients receiving immune checkpoint inhibitors. MATERIALS & METHODS: Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012–2019. RESULTS: A total of 554 patients received ICIs of which 123 developed an immune related adverse event. Twenty one (17%) with toxicity were identified as having a pre-existing autoimmune disease and 88 required treatment with corticosteroids or hormone replacement. Thirty two (26%) out of 123 had to temporarily discontinue ICIs due to autoimmune manifestations. Endocrine and skin manifestations were the most prevalent immune disorders in our cohort. In melanoma better efficacy was seen in patients with immune toxicity. CONCLUSION: Autoimmune diseases appear in patients receiving ICIs in this real world experience. Our results differ from other series on the frequency of autoimmunity. Complete discontinuation of ICIs due to autoimmunity was rare. Future Science Ltd 2020-11-23 /pmc/articles/PMC7787148/ /pubmed/33437507 http://dx.doi.org/10.2144/fsoa-2020-0129 Text en © 2020 Morton Scheinberg This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Short Communication Schmerling, Rafael A Buzaid, Antonio C Haddad, Carolina K Schutz, Fabio AB Kater, Fabio R Pimenta, Juliana Maluf, Fernando William, William N Lopes, Camila Bromberg, Dafne R Oliveira, Ana C Golmia, Ricardo Scheinberg, Morton Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title | Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title_full | Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title_fullStr | Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title_full_unstemmed | Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title_short | Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review |
title_sort | immune manifestations with checkpoint inhibitors in a single brazilian center: experience and literature review |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787148/ https://www.ncbi.nlm.nih.gov/pubmed/33437507 http://dx.doi.org/10.2144/fsoa-2020-0129 |
work_keys_str_mv | AT schmerlingrafaela immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT buzaidantonioc immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT haddadcarolinak immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT schutzfabioab immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT katerfabior immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT pimentajuliana immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT maluffernando immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT williamwilliamn immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT lopescamila immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT brombergdafner immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT oliveiraanac immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT golmiaricardo immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview AT scheinbergmorton immunemanifestationswithcheckpointinhibitorsinasinglebraziliancenterexperienceandliteraturereview |